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ABSTRACT
Pre-exposure prophylaxis (PrEP) offers a
promising new approach to HIV prevention. It
is protective against HIV infection across
populations and has few significant safety risks
and little evidence of behavioural risk
compensation. This article summarises the
evidence behind HIV PrEP as an intervention,
populations that may benefit, current
guidelines and programmes, and the
cost-effectiveness modelling of this strategy.
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INTRODUCTION
Despite significant advances in treatment, HIV
infection remains a very significant burden on
individuals, communities, healthcare systems
and economies around the world. HIV
incidence rates remain stable and costs
unsustainable, making HIV a public health
priority. The use of pre-exposure prophylaxis
(PrEP) in HIV-negative individuals who are at
high risk of HIV acquisition is an emerging
strategy to add to the toolbox of HIV
prevention. This article summarises the
evidence behind HIV PrEP as an intervention,
populations that may benefit, current
guidelines and programmes, and the
cost-effectiveness modelling of this strategy.
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EVIDENCE FOR PREP
Tenofovir Disoproxil Fumarate-Based PrEP
Ten randomised controlled trials have
investigated the use of PrEP utilising tenofovir,
five providing evidence for the effectiveness of
daily oral tenofovir disoproxil fumarate [1, 2] or
Truvada (tenofovir disoproxil fumarate/
emtricitabine fixed dose combination tablet)
[3–5], one for event-driven Truvada taken
before and after sex [6], two for event-driven
topical tenofovir gel [7, 8] and two for daily
tenofovir vaginal gel [9, 10].
Effectiveness for oral tenofovir-based
regimens has been demonstrated in men who
have sex with men (MSM) [3, 4, 6], heterosexual
serodiscordant couples [1], young heterosexual
adults (male and female) [5]) and injecting drug
users [2]. Tenofovir 1% vaginal gel applied
before and after sex resulted in a modest
reduction in HIV incidence in women in
Kwazulu-Natal [7] but no reduction in a
further trial conducted in South Africa [8].
Two randomised placebo-controlled trials
conducted in women in Sub-Saharan Africa
observed no benefit for daily oral tenofovir or
Truvada or daily tenofovir 1% vaginal gel
[9, 10]; these studies however experienced low
levels of retention and adherence, and
biological efficacy is supported by subset
analyses in women using gel who had
detectable drug in plasma (and demonstrated
protection) [8, 10].
Main Tenofovir PrEP Studies
The iPrEx study was a double-blind,
placebo-controlled study of daily
Truvada-based PrEP in men and
male-to-female transgender adults who
reported sex with men in the 6 months prior
to enrolment in 6 countries. An overall 44% risk
reduction was seen, which increased to 73%
where self-reported adherence was[90% and to
92% in those with detectable plasma drug levels
[4]. In the open-label extension of the iPrEx
study (iPrEx OLE), 100% efficacy was reached in
those taking four or more doses a week [11].
More recently two randomised trials using
Truvada in European MSM populations were
reported. PROUD was an open-label design
(daily Truvada versus no drug) [3] and
IPERGAY a placebo-controlled design
evaluating event-based Truvada (two tablets
before sex and one a day for 2 days after the
last condomless anal sex act) [6]. In both trials
the HIV incidence in the control group was
much higher than anticipated, 9.0/100 person
years in PROUD and 6.6/100 person years in
IPERGAY. Indeed the incidence in PROUD was
seven fold higher than in MSM attending sexual
health clinics. The reductions in HIV
acquisition in both trials (by ITT analysis) were
86%, which is the highest efficacy observed in
PrEP trials to date. Interestingly, IPERGAY
achieved this using half the number of doses
compared to daily dosing of the drug. Concern
that PrEP would reduce condom use when
knowingly taking PrEP was assessed in the
open-label PROUD study whereby patients
knew whether they were taking effective PrEP
or not and no difference was found in sexually
transmitted infections between the groups [3].
One study (from Thailand) has explored
tenofovir-based PrEP in preventing HIV
transmission via intravenous drug use and
found an almost 50% risk reduction in HIV
acquisition [2].
Non-Tenofovir-based PrEP
Tenofovir-based PrEP is not without potential
toxicities with reduction in bone mineral
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density [12, 13] and renal function [14]
observed albeit in low numbers. As a result
other PrEP agents are being investigated:
tenofovir alafenamide (TAF) is a pro-drug of
tenofovir with theoretical advantages in terms
of decreased renal and bone adverse events and
decreased monitoring requirements. However,
although macaque data appear promising [15],
there are presently no efficacy data in humans
and vaginal drug levels appear to be lower than
those achieved with tenofovir disoproxil [16].
Whether 3TC could be used instead of FTC in
PrEP has not been evaluated in a clinical trial;
however, a systematic review and meta-analysis
of randomised trials concluded that there would
be comparative efficacy of lamivudine and
emtricitabine for PrEP efficacy (p = 0.88) [17]
(Table 1).
Maraviroc has not shown protection from
HIV in ex-vivo challenge models, whether via
stat dosing across rectal and vaginal mucosa or
daily dosing across rectal mucosa [18, 19].
Taken orally in combination with other
antiretroviral agents, Maraviroc is well
tolerated but PrEP efficacy is not known
[20, 21]. Cabotegravir (as 2-monthly
injections) also shows promise [22] and a
phase 3 efficacy study is underway. Two
randomised control trials of the dapivirine
intravaginal ring reported consistent results.
Although the ITT benefit was small, post hoc
analyses excluding younger women (less than
25 years of age) who were less likely to have
detectable drug revealed modest protection
benefits [61% (32–77) risk reduction] [23].
PROS AND CONS OF DAILY
AND EVENT-DRIVEN ORAL PREP
The two current main models of oral PrEP are
daily dosing (tenofovir disoproxil fumarate or
Truvada) (as in iPrEX and PROUD) or
event-driven usage (as in IPERGAY). Both
strategies have demonstrated utility in trials,
but their applicability may differ between
populations and settings.
Daily PrEP
Daily tenofovir-based PrEP has shown good
efficacy in a variety of populations, but
requires good adherence and frequent repeat
HIV testing to minimise the associated
antiretroviral resistance that can occur as a
consequence of PrEP failure [24]. It can also
lead to drug wastage if taken during periods of
low sexual risk and potentially cause toxicity
(principally bone and renal) if taken long term
[25]. Renal and bone monitoring may be
unavailable or operationally difficult and
costly (especially in resource-poor/remote
settings), and toxicities may differentially
affect specific populations. For example, bone
loss (which is pronounced in adolescents) is of
particular concern in countries such as
Botswana where up to 7% of healthy young
adults have low bone mineral density [12].
Event-Driven PrEP
Event-driven PrEP has only been investigated in
MSM populations (and therefore efficacy is
unproven with heterosexual or needle-based
transmission). If efficacy is substantiated in
future studies, this strategy has the potential
to improve cost effectiveness, whilst reducing
drug wastage, reduce toxicity and monitoring
requirements—as there will be natural
interruptions during periods of no risk.
Furthermore, in contrast to daily PrEP,
event-driven PrEP has not (to date) led to any
cases of drug-resistant HIV. However this may
change as implementation is rolled out.
Transmitted tenofovir resistance is already a
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Table 1 Key studies examining efﬁcacy of Tenofovir-based PrEP
Route of
exposure








44% reduction in the incidence of HIV (95% conﬁdence
interval [CI] 15–63; p = 0.005) [4]
Y
N = 275 (in immediate PrEP group)
Relative reduction 86% (90% CI 64-96, p = 00001;











Reduction of 489% in incidence (95% CI 96–722;





Tenofovir disproxil fumarate N = 1584











Efﬁcacy 62.2% (95% CI 21.5–83.4; p = 0.03) [5]
Y
Women 1% Tenofovir Vaginal Gel N = 445
Estimated reduction of 39% overall
(54% in women with high gel adherence) [7]
Y
N = 2059 total (gel or placebo)
Incidence rate ratio 1.0 (95% CI 0.7–1.4) [8]
N
N = 996











Hazard ratio 0.94 (95% CI 0.59–1.52; p = 0.81) [9]
N
N = 985
Hazard ratio 1.04 (95% CI 0.73–1.49) [10]
N
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concern in Sub-Saharan Africa, South/Southeast
Asia and the Latin America/Caribbean region
[24, 26–29]; it is essential that PrEP does not
drive drug resistance, further reducing
treatment options for HIV-positive individuals.
The main practical limitation of
event-driven PrEP is the complexity of the
IPERGAY regime, which has led to concerns
that adherence may be difficult. As such further
evaluation in a variety of settings and risk
groups is required. Furthermore, this regimen
is not indicated in those with active hepatitis B
infection because of the risk of hepatic flares
when the drug is interrupted.
Overall, the critical factors when deciding
upon a PrEP regimen are adherence and the
evidence base for the individual in question.
Data support daily PrEP in MSM, heterosexual
men and heterosexual women. However, data
for event-based PrEP are limited to MSM only
(one study only) and further data on tenofovir
in women are desirable. It is likely that, as for
HIV acquisition risk, PrEP requirements may




Understanding the cultural context of PrEP
provision is vital for implementation with
factors such as sexual practice, age and gender
playing important roles in HIV acquisition risk
and acceptability of interventions. One model
of PrEP provision therefore does not fit all
communities or scenarios. For instance, the
failure of the PrEP trials in women in Africa
has been attributed to cultural and social factors
including concerns of disclosure to male
partners [9, 10]. Societal and personal factors
affecting the acceptability and adherence to
PrEP are being explored in a variety of
populations.
Since 2013 PrEP implementation has
accelerated in the US where Truvada is
licenced for use (FDA) [31] and has been used
with this indication by more than 50,000
individuals [32], and PrEP has been included
in the European AIDS Clinical Society (EACS)
[33] and World Health Organisation (WHO)
guidelines [34]. Pressure has increased globally
for countries to submit to regulatory authorities
and include PrEP in national policies.
Europe EACS guidelines advise tenofovir or
Truvada daily as PrEP for heterosexuals at risk
and Truvada daily or event-driven for MSM [35].
The European Centre for Disease Control
revised their previous statement, which
expressed concern about risk compensation, to
recommend that ‘‘EU Member States should
give consideration to integrating PrEP into their
existing HIV prevention package for those most
at-risk of HIV infection, starting with MSM.’’
The European Medicines Agency has recently
recommended a market authorisation for
Truvada as PrEP in high-risk individuals (EMA
[36]).
USA In the US, PrEP has been licenced for
4 years with numbers continuing to increase
[32]. The CDC [37] has recommended daily
Truvada-based PrEP for MSM, heterosexual men
and women, and active injecting drug users
who are at on-going risk of HIV acquisition,
once HIV has been excluded. It also
recommends that Tenofovir alone can be
considered in non-MSM individuals, but
event-based PrEP is not advocated.
Australia Truvada has been approved by
Australia’s Therapeutic Goods Administration
for use as PrEP [38] but to date has not been
agreed via the Pharmaceutical Benefits
Scheme—and therefore can be obtained but
only at full drug cost to the individual.
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Global The WHO recommends daily PrEP
(Tenofovir and Truvada) for people at
substantial risk of acquiring HIV infection but
does not recommend event-driven PrEP [34].
EFFECTIVENESS AND COST
EFFECTIVENESS
The key factor to determine the utility and
priority of PrEP in a community or population is
its effectiveness as an intervention. From a
clinical and public health perspective the
effectiveness could be considered as the
number needing to access PrEP to prevent one
new infection, and from the health economic
and payer’s viewpoint it would include the
overall cost-effectiveness. Both effectiveness
and cost-effectiveness depend on the efficacy
and continued adherence to the intervention
and on the risks/incidence rates of HIV
acquisition in those not receiving PrEP. Cost
effectiveness also includes the costs of the drug,
monitoring and follow-up, as well as costs
avoided by decreasing new infections. A
further issue is analysis of how PrEP compares
to different interventions (such as promotion of
condom use, circumcision, antiretroviral
treatment for those diagnosed HIV positive
and frequent testing of high-risk HIV-negative
individuals).
As a consequence of the high HIV incidence
in the control/placebo groups in the PROUD
and IPERGAY studies, and the large effect size in
both trials, the number of MSM needed to treat
to avert one infection in a year was very low (13
and 18 respectively). A preliminary
cost-effectiveness evaluation using the
eligibility criteria for these two trials and the
86% reduction in HIV incidence suggested that
daily PrEP for MSM will be cost-effective if HIV
testing continues at the current rate and there is
no substantial change in the proportion of MSM
who manage their risk with condoms [39]. The
usage and cost of drug could be substantially
reduced with an event-based regimen. The cost
of drug will also reduce when tenofovir comes
off patent (in Europe, the USA and Australia
2017/2018; emtricitabine no longer has a patent
applied) provided a two-tablet regimen proves
acceptable to potential subjects or a generic
single tablet is marketed.
Modelling of individuals at high risk of HIV
acquisition showed low incremental
cost-effectiveness ratios (ICER) and costs per
quality-adjusted life year (QALY) estimates
[40, 41]. PrEP has been calculated to be cost
effective in high-risk MSM and heterosexual
discordant couples [42, 43, 44, 46].
Furthermore, demonstration projects in MSM
in the USA have shown that study effectiveness
translates into real-life experience [45].
However although PrEP in such populations is
highly clinically effective (with a stronger
evidence base than behavioural interventions)
it is costly in the short term with a high budget
impact. Indeed the benefits for MSM in the UK
may take 40? years to realise [46].
Modelling has shown that the most effective
method of decreasing HIV incidence is through
combination interventions. For intravenous
drug users in the US, PrEP combined with
frequent HIV testing as well as the
commencement of ART for all those HIV
positive was the most effective package at
reducing incidence—however the costs were
dramatically increased and cost-effectiveness
decreased compared to single prevention
strategies [47]. In Nigeria, the most effective
intervention was modelled to be a combination
of treatment of HIV-positive partners and
condom promotion rather than PrEP [48].
Similar modelling in Zambia and South Africa
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confirmed the larger impact of treatment of
positive individuals at earlier stages of disease
over PrEP [49]. Therefore, with limited
resources, PrEP may not be the primary
intervention chosen in some settings.
If other prevention methodologies, such as
increased diagnosing of the undiagnosed and
offering efficacious anti-retrovirals to all those
known positive (pursuing the UNAIDS 90-90-90
programme), are improved then PrEP may have
a decreased potential impact and role [50]. A
separate consideration is that highly targeted
strategies, focussing on the most cost-effective
groups only, may not have large
population-level impacts [51]. It is therefore
important for a country to determine the
preferred outcomes and direct interventions
accordingly.
CONCLUSIONS
PrEP can be a highly effective HIV prevention
strategy to be added to the toolbox of HIV
prevention. Establishing a place for this tool in
HIV prevention in specific populations is highly
influenced by drug cost, user acceptability and
political will. Together with treatment as
prevention and other interventions, PrEP
provides a significant opportunity to reduce
HIV incidence significantly and should be a
high priority for consideration by health
systems and funders.
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